StockNews.AI
AMPH
StockNews.AI
104 days

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

1. Amphastar reported $170.5 million in Q1 2025 revenues. 2. CEO expressed confidence in growth from BAQSIMI® and Primatene MIST®.

2m saved
Insight
Article

FAQ

Why Bullish?

Strong revenue and earnings indicate robust operational performance, similar to prior quarterly successes.

How important is it?

Financial performance and positive CEO outlook are significant for investors assessing AMPH's growth.

Why Short Term?

Immediate investor confidence likely due to quarterly results, impacting stock in the near term.

Related Companies

PFEJNJBNTX
Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2025. First Quarter Highlights Net revenues of $170.5 million for the first quarter GAAP net income of $25.3 million, or $0.51 per share, for the first quarter Adjusted non-GAAP net income of $36.9 million, or $0.74 per share, for the first quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are confident in the potential of our portfolio, particularly with the growth of BAQSIMI® and Primatene MIST®, and the promising pipeline of biosimilars and proprietary products.

Related News